
Olio Labs
Olio Labs is a YC Summer 2023 (S23) company. Based in Remote. Team of 5.
About Olio Labs
Summary
Olio Labs develops AI-driven combination therapeutics for complex diseases, starting with obesity. Where conventional drugs target one or two proteins, Olio Labs models thousands of interacting proteins simultaneously and searches trillions of drug combinations to identify candidates with greater efficacy and fewer side effects than existing GLP-1 treatments like semaglutide. The work replaces traditional trial-and-error combination screening in early-stage drug discovery.
From the Y Combinator listing
Combination therapeutics for the world's toughest diseases
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Remote
- 5
- Active
- Early
Founders (2)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works